2. Protein Tyrosine Kinase/RTK
  3. VEGFR PDGFR FGFR
  4. SU10944

SU10944 is a selective, orally active VEGFR inhibitor, with an IC50 of 6 nM against VEGFR-1, an IC50 of 96 nM and a Ki of 21 nM against VEGFR-2. SU10944 only exhibits weak inhibitory activity against PDGFRβ (IC50 = 1 μM), SCFR (IC50 = 1.58 μM) and FGFR-1 (IC50 = 1.6 μM). SU10944 selectively inhibits VEGFR receptor downstream signaling, neovascularization, vascular permeability, VEGF-mediated tissue factor production, and induces tumor growth delay. SU10944 can be used in research related to diabetic retinopathy, exudative age-related macular degeneration or cancer.

For research use only. We do not sell to patients.

SU10944

SU10944 Chemical Structure

CAS No. : 515821-11-1

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

SU10944 Related Antibodies

Top Publications Citing Use of Products

View All VEGFR Isoform Specific Products:

View All Isoforms
VEGFR1/Flt-1 VEGFR2/KDR/Flk-1 VEGFR3/Flt-4

View All PDGFR Isoform Specific Products:

View All Isoforms
PDGFR PDGFRβ PDGFRα

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

SU10944 is a selective, orally active VEGFR inhibitor, with an IC50 of 6 nM against VEGFR-1, an IC50 of 96 nM and a Ki of 21 nM against VEGFR-2. SU10944 only exhibits weak inhibitory activity against PDGFRβ (IC50 = 1 μM), SCFR (IC50 = 1.58 μM) and FGFR-1 (IC50 = 1.6 μM). SU10944 selectively inhibits VEGFR receptor downstream signaling, neovascularization, vascular permeability, VEGF-mediated tissue factor production, and induces tumor growth delay. SU10944 can be used in research related to diabetic retinopathy, exudative age-related macular degeneration or cancer[1][2].

IC50 & Target[1]

VEGFR1

6 nM (IC50)

VEGFR2

96 nM (IC50)

FGFR1

1/6 μM (IC50)

In Vitro

SU10944 (2 h) inhibits VEGFR-2 autophosphorylation in transiently transfected human embryonic kidney 293T cells with an IC50 of 227 nM[1].
SU10944 (0.2-25 μM; 20 h) dose-dependently inhibits VEGF-induced VEGFR-2 autophosphorylation in stably transfected NIH/3T3 cells, with maximal inhibition at 25 μM[1].
SU10944 (varying concentrations; 4 h) inhibits VEGF-induced tissue factor production in human umbilical vein endothelial cells with an IC50 of 102 nM, without affecting PMA-stimulated tissue factor production[1].
SU10944 (varying concentrations; 20 h (3T3 assays); 3 days (MO7e assay)) inhibits SCFR-dependent MO7e cell survival (IC50 = 1.6 μM) and PDGFRβ-dependent 3T3 cell proliferation (IC50 = 30.6 μM), but does not inhibit EGFR- or FGFR-1-dependent 3T3 cell proliferation (IC50 > 50 μM) and is not cytotoxic to 3T3 cells at concentrations up to 50 μM[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

SU10944 Related Antibodies

Western Blot Analysis[1]

Cell Line: NIH/3T3 cells (stably expressing mouse VEGFR-2)
Concentration: 0.2, 1, 5 and 25 μM
Incubation Time: 20 h
Result: Dose-dependently inhibited VEGF-induced VEGFR-2 autophosphorylation, with near-complete inhibition at 25 μM.
In Vivo

SU10944 (3-300 mg/kg; p.o.) dose-dependently inhibits VEGF-induced corneal neovascularization in rats, with a maximum 95% inhibition at 300 mg/kg and an ED50 of ~30 mg/kg for the sodium salt formulation[1].
SU10944 (3-100 mg/kg; p.o.; single dose) time- and dose-dependently inhibits VEGF-induced vascular permeability in athymic mice, with a plasma concentration of 250 ng/mL correlating to 50% inhibition[1].
SU10944 (150 mg/kg; p.o.; once daily; 12 days) induces 76% growth inhibition of C6 glioma xenografts in nu/nu mice, accompanied by modest antiangiogenic activity[2].
SU10944 (150 mg/kg; p.o.; once daily; 15 days) induces 95% growth inhibition and maintains stasis of MV4;11 leukemia xenografts in nu/nu mice, with modest antiangiogenic activity[2].
SU10944 (150 mg/kg; p.o.; once daily; 18 days) induces 55% growth inhibition of HT-29 colon carcinoma xenografts in nu/nu mice[2].
SU10944 (150 mg/kg; p.o.; once daily; 14 days) induces 90% growth inhibition of 786-O renal carcinoma xenografts in nu/nu mice, accompanied by significant antiangiogenic activity[2].
SU10944 (150 mg/kg; p.o.; once daily; 29 days) induces 82% growth inhibition of WM-266-4 melanoma xenografts in nu/nu mice, with modest antiangiogenic activity[2].
SU10944 (150 mg/kg; p.o.; once daily; 14 days) induces 28% growth inhibition of H226 lung carcinoma xenografts in nu/nu mice, with moderate antiangiogenic activity[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Athymic[1]
Dosage: 3 mg/kg; 30 mg/kg; 100 mg/kg
Administration: p.o.; single dose
Result: Inhibited VEGF-induced vascular permeability in a time- and dose-dependent manner.
Sustained maximum inhibition up to 2 hours at 100 mg/kg, with 50% inhibition still apparent 24 hours postdose.
Showed maximum inhibition at 1 hour and decreased to zero by 24 hours at 30 mg/kg.
Associated 50% inhibition of VEGF-mediated vascular permeability with a plasma concentration of 250 ng/mL (844 nM).
Animal Model: nu/nu (female, 8-12 weeks old, 25 g, rat C6 glioma cells implanted s.c. into hindflank)[2]
Dosage: 150 mg/kg
Administration: p.o.; once daily; 12 days
Result: Induced 76% tumor growth inhibition.
Reduced tumor microvessel density (MVD) by 20% relative to vehicle-treated controls.
Animal Model: nu/nu (female, 8-12 weeks old, 25 g, human MV4;11 FLT3-ITD-mutated leukemia cells implanted s.c. into hindflank with 50% Matrigel)[2]
Dosage: 150 mg/kg
Administration: p.o.; once daily; 15 days
Result: Induced 95% tumor growth inhibition.
Maintained tumor stasis.
Reduced tumor microvessel density (MVD) by 40% relative to vehicle-treated controls.
Animal Model: nu/nu (female, 8-12 weeks old, 25 g, human HT-29 colon carcinoma cells implanted s.c. into hindflank with 50% Matrigel)[2]
Dosage: 150 mg/kg
Administration: p.o.; once daily; 18 days
Result: Induced 55% tumor growth inhibition.
Animal Model: nu/nu (female, 8-12 weeks old, 25 g, human 786-O renal carcinoma cells implanted s.c. into hindflank with 50% Matrigel)[2]
Dosage: 150 mg/kg
Administration: p.o.; once daily; 14 days
Result: Induced 90% tumor growth inhibition.
Reduced tumor microvessel density (MVD) by 54% relative to vehicle-treated controls.
Animal Model: nu/nu (female, 8-12 weeks old, 25 g, human WM-266-4 melanoma cells implanted s.c. into hindflank)[2]
Dosage: 150 mg/kg
Administration: p.o.; once daily; 29 days
Result: Induced 82% tumor growth inhibition.
Reduced tumor microvessel density (MVD) by 23% relative to vehicle-treated controls.
Animal Model: nu/nu (female, 8-12 weeks old, 25 g, human H226 lung carcinoma cells implanted s.c. into hindflank)[2]
Dosage: 150 mg/kg
Administration: p.o.; once daily; 14 days
Result: Induced 28% tumor growth inhibition.
Reduced tumor microvessel density (MVD) by 42% relative to vehicle-treated controls.
Molecular Weight

296.33

Formula

C17H16N2O3
CAS No.
SMILES

O=C(O)CCC=1C=C(NC1C=C2C(=O)NC=3C=CC=CC32)C
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

SU10944 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

SU10944515821-11-1SU 10944SU-10944VEGFRPDGFRFGFRVascular endothelial growth factor receptorPlatelet-derived growth factor receptorFibroblast growth factor receptorNIH/3T3 cellsSCFRgliomahuman umbilical vein endothelial cellsVEGFR-1VEGFR-2FGFR-1MO7e cellshuman embryonic kidney 293T cellsPDGFRβInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
SU10944
Cat. No.:
HY-135435
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.